Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JS 009

Next Previous
Search
Drug Profile

JS 009

Alternative Names: JS-009; TAB-009

Latest Information Update: 12 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Junshi Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 12 Apr 2023 Preclinical development in Solid-tumours is ongoing in China (Parenteral) (Shanghai Junshi Biosciences pipeline, April 2023)
  • 03 Apr 2023 Shanghai Junshi Bioscience withdraws a phase I trial (Combination therapy, Monotherapy, late-stage disease, Metastatic diseases) for Solid tumours due to the research and develop strategy of product JS 009 adjustment (NCT05650203)
  • 30 Mar 2023 Phase-I clinical trials in Solid tumours in China (Parenteral) (Shanghai Junshi Biosciences pipeline, April 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top